Short Telomere Syndrome: Implications for MDS and AML Patients | Aplastic Anemia & MDS International Foundation

Short Telomere Syndrome: Implications for MDS and AML Patients

Presenter(s): 
Topic(s): 
Related Bone Marrow Failure Diseases and Malignancies
Aplastic Anemia
Myelodysplastic Syndromes (MDS)
Acute Myeloid Leukemia (AML)
Presentation Date: 
Thursday, November 19, 2020

Short telomere syndrome is a genetic mutation that has significant implications for MDS and AML patients. This webinar provides an overview of the subject and will address the specific impact for bone marrow failure disease patients. Our speaker, Mary Armanios, M.D., is the Clinical Director of the Telomere Center at Johns Hopkins, Associate Director of Cancer Research Career Enhancement, Sidney Kimmel Comprehensive Cancer Center, Professor of Oncology, Genetic Medicine, Molecular Biology and Genetics, and Pathology as well as an active researcher. Dr. Armanios focuses her research on disorders caused by telomere dysfunction and specific to this webinar, the implications for patients with MDS and AML.